SAN DIEGO, April 12, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will webcast its Quarterly Update Conference Call for the first quarter of 2010 on Monday, April 19, 2010 at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date pre-market, Amylin will release financial results for the first quarter of 2010.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN((R)) (pramlintide acetate) injection and BYETTA((R)) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.
CONTACT: Media, Anne Erickson, +1-858-754-4443, anne.erickson@amylin.com,
or Investors, Michael York, +1-858-458-8602, michael.york@amylin.com, both
of Amylin Pharmaceuticals, Inc.
Web site: http://www.amylin.com/
